Skip to content
10-Q

Quarterly Report

Adamas Pharmaceuticals, Inc.

0001328143-21-000075

← back to feed
Filed
Nov 10, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2021 · Oct 31, 2021 45.79M sh
Shares Diluted Q3 2021 · Sep 30, 2021 45.62M sh
Shares Diluted Q3 2021 · Sep 30, 2021 42.12M sh
Shares Diluted Q3 2021 · Sep 30, 2020 28.38M sh
Shares Diluted Q3 2021 · Sep 30, 2020 28.2M sh
Capex Q3 2021 · Sep 30, 2021 $38K
Capex Q3 2021 · Sep 30, 2020 $0
Operating Cash Flow Q3 2021 · Sep 30, 2021 −$36.49M
Operating Cash Flow Q3 2021 · Sep 30, 2020 −$40.38M
Long Term Debt Q3 2021 · Sep 30, 2021 $124.48M
Long Term Debt Q3 2021 · Dec 31, 2020 $126.31M
Short Term Debt Q3 2021 · Sep 30, 2021 $4.55M
Short Term Debt Q3 2021 · Dec 31, 2020 $3.66M
Short Term Investments Q3 2021 · Sep 30, 2021 $4.48M
Short Term Investments Q3 2021 · Dec 31, 2020 $11.71M
Cash And Equivalents Q3 2021 · Sep 30, 2021 $78.62M
Cash And Equivalents Q3 2021 · Dec 31, 2020 $71.66M
Stockholders Equity Q3 2021 · Sep 30, 2021 −$21.61M
Stockholders Equity Q3 2021 · Jun 30, 2021 −$4.03M
Stockholders Equity Q3 2021 · Mar 31, 2021 $5.94M
Stockholders Equity Q3 2021 · Dec 31, 2020 −$49.98M
Stockholders Equity Q3 2021 · Sep 30, 2020 −$34.62M
Stockholders Equity Q3 2021 · Jun 30, 2020 −$24.41M
Stockholders Equity Q3 2021 · Mar 31, 2020 −$15.85M
Stockholders Equity Q3 2021 · Dec 31, 2019 −$893K
Current Liabilities Q3 2021 · Sep 30, 2021 $23.84M
Current Liabilities Q3 2021 · Dec 31, 2020 $34.87M
Total Liabilities Q3 2021 · Sep 30, 2021 $165.58M
Total Liabilities Q3 2021 · Dec 31, 2020 $170.01M
Current Assets Q3 2021 · Sep 30, 2021 $108M
Current Assets Q3 2021 · Dec 31, 2020 $111.74M
Total Assets Q3 2021 · Sep 30, 2021 $143.98M
Total Assets Q3 2021 · Dec 31, 2020 $120.03M
Eps Diluted Q3 2021 · Sep 30, 2021 −$0.43
Eps Diluted Q3 2021 · Sep 30, 2021 −$1.05
Eps Diluted Q3 2021 · Sep 30, 2020 −$0.42
Eps Diluted Q3 2021 · Sep 30, 2020 −$1.39
Eps Basic Q3 2021 · Sep 30, 2021 −$0.43
Eps Basic Q3 2021 · Sep 30, 2021 −$1.05
Eps Basic Q3 2021 · Sep 30, 2020 −$0.42
Eps Basic Q3 2021 · Sep 30, 2020 −$1.39
Sga Expense Q3 2021 · Sep 30, 2021 $29.73M
Sga Expense Q3 2021 · Sep 30, 2021 $85.52M
Sga Expense Q3 2021 · Sep 30, 2020 $26.12M
Sga Expense Q3 2021 · Sep 30, 2020 $73.85M
Rd Expense Q3 2021 · Sep 30, 2021 $1.23M
Rd Expense Q3 2021 · Sep 30, 2021 $4.49M
Rd Expense Q3 2021 · Sep 30, 2020 $2.33M
Rd Expense Q3 2021 · Sep 30, 2020 $7.35M
Net Income Q3 2021 · Sep 30, 2021 −$19.52M
Net Income Q3 2021 · Sep 30, 2021 −$44.44M
Net Income Q3 2021 · Jun 30, 2021 −$12.34M
Net Income Q3 2021 · Mar 31, 2021 −$12.57M
Net Income Q3 2021 · Sep 30, 2020 −$11.92M
Net Income Q3 2021 · Sep 30, 2020 −$39.13M
Net Income Q3 2021 · Jun 30, 2020 −$10.57M
Net Income Q3 2021 · Mar 31, 2020 −$16.65M
Operating Income Q3 2021 · Sep 30, 2021 −$5.64M
Operating Income Q3 2021 · Sep 30, 2021 −$24.32M
Operating Income Q3 2021 · Sep 30, 2020 −$8.77M
Operating Income Q3 2021 · Sep 30, 2020 −$29.19M
Cost Of Revenue Q3 2021 · Sep 30, 2021 $576K
Cost Of Revenue Q3 2021 · Sep 30, 2021 $1.49M
Cost Of Revenue Q3 2021 · Sep 30, 2020 $488K
Cost Of Revenue Q3 2021 · Sep 30, 2020 $1.44M
Revenue Q3 2021 · Sep 30, 2021 $25.9M
Revenue Q3 2021 · Sep 30, 2021 $67.18M
Revenue Q3 2021 · Sep 30, 2020 $20.18M
Revenue Q3 2021 · Sep 30, 2020 $53.45M